High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).
暂无分享,去创建一个
W. Hiddemann | C. Huber | M. Dreyling | M. Unterhalt | G. Hess | R. Weide | C. Losem | J. Heymanns | A. Aldaoud | H. Koeppler | S. Schmitz | U. Haak | J. Thomalla